Form 4: C4 Therapeutics Director, Kenneth Carl Anderson, Acquires Shares in Lieu of Cash Compensation

Director Kenneth Carl Anderson acquired 2,023 shares of C4 Therapeutics common stock at $5.56 per share in lieu of cash compensation.

Summary

• On October 1, 2024, Kenneth Carl Anderson, a director of C4 Therapeutics, acquired 2,023 shares of common stock.
• The shares were issued as compensation for services as a non-employee director, in lieu of cash, according to the Issuer's Non-Employee Director Compensation Policy.
• The price per share was $5.56, based on the closing market price of C4 Therapeutics common stock on October 1, 2024.
• Following the transaction, Anderson directly owns 116,694 shares.
• Anderson also has indirect ownership through spousal holdings and grantor retained annuity trusts.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares in lieu of cash suggests confidence, but it's a routine transaction.

Positives

• A director's decision to take compensation in stock may signal confidence in the company's future performance.

Industry Context

Director share acquisitions are common in the biotech industry as part of compensation packages, aligning director interests with shareholder value.

Comparison to Industry Standards

• Director compensation packages vary across the biotech industry, with some companies offering a mix of cash and stock options, while others provide shares directly.
• Comparing C4 Therapeutics' director compensation policy to companies like Amgen, Biogen, or Gilead Sciences would provide a benchmark for industry standards.
• The specific amount of stock awarded to directors often depends on the company's size, performance, and overall compensation strategy.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals director confidence.

Key Dates